GleamWall
中文EN

ORIC Oric Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1796280 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-15.2%
TTM EPS YoY15.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-41.8%
ROA-39.1%
ROIC (approx.)-40.8%
Asset turnover—

Leverage & solvency

Liabilities / assets7.5%
Debt / equity0.00x
Current ratio11.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$43.36M$36.30M$31.44M$25.86M$28.77M$30.55M$24.64M$31.97M
SG&A expense$8.19M$9.00M$8.18M$8.70M$7.90M$8.52M$8.08M$7.60M
Operating income-$51.55M-$45.30M-$39.62M-$34.55M-$36.67M-$39.06M-$32.72M-$39.57M
Net income-$48.08M-$41.49M-$35.77M-$30.50M-$32.59M-$36.35M-$30.02M-$36.31M
EBITDA-$51.27M-$45.03M-$39.35M-$34.23M-$36.38M-$38.75M-$32.42M-$39.27M
EPS (basic)-0.44-0.38-0.34—-0.33-0.47-0.42—
EPS (diluted)-0.44-0.38-0.34—-0.33-0.47-0.42—
Weighted avg. shares (diluted)108.18M108.01M105.47M—98.95M78.13M71.04M—
Balance sheet
Cash & equivalents$33.85M$37.48M$56.40M$45.67M$49.67M$75.86M$49.33M$59.90M
Short-term investments$227.53M$227.28M$225.54M$235.82M$237.47M$206.65M$154.39M$196.55M
Current assets$274.75M$273.69M$290.23M$288.47M$295.59M$291.12M$211.43M$262.25M
PP&E, net$2.08M$2.24M$2.15M$2.42M$2.56M$2.76M$3.02M$2.92M
Total assets$366.89M$404.69M$436.76M$408.89M$431.19M$346.86M$242.86M$274.14M
Current liabilities$24.78M$20.76M$17.77M$20.42M$20.18M$18.05M$17.62M$24.85M
Total liabilities$27.38M$23.43M$21.20M$24.53M$24.27M$22.86M$23.12M$31.02M
Shareholders' equity$339.50M$381.26M$415.56M$384.36M$406.92M$324.00M$219.74M$243.12M
Shares outstanding103.87M103.64M103.49M98.53M97.28M86.19M71.08M71.02M
Cash flow statement
Operating cash flow-$41.99M-$31.61M-$32.44M-$22.48M-$25.11M-$30.84M-$32.53M-$28.05M
Capital expenditure$107,000$356,000$2,000$227,000$35,000$63,000$387,000$219,000
Free cash flow-$42.09M-$31.96M-$32.44M-$22.71M-$25.15M-$30.91M-$32.92M-$28.27M
Investing cash flow$37.54M$11.86M-$17.98M$16.98M-$110.53M-$76.93M$22.45M$42.66M
Financing cash flow$806,000$828,000$61.14M$1.50M$109.45M$134.30M$11,000$575,000
Depreciation & amortization$279,000$264,000$270,000$320,000$288,000$310,000$302,000$304,000
Stock-based compensation$6.19M$7.09M$6.90M$6.28M$5.63M$6.57M$6.55M$5.20M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.